Citadel Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-203,159
| Closed | -$401K | – | 15889 |
|
|
2022
Q4 | $380K | Buy |
203,159
+161,276
| +385% | +$402K | ﹤0.01% | 8824 |
|
|
2022
Q3 | $108K | Sell |
41,883
-57,979
| -58% | -$144K | ﹤0.01% | 11025 |
|
|
2022
Q2 | $193K | Sell |
99,862
-11,160
| -10% | -$24.4K | ﹤0.01% | 10737 |
|
|
2022
Q1 | $330K | Sell |
111,022
-58,626
| -35% | -$221K | ﹤0.01% | 10372 |
|
|
2021
Q4 | $762K | Buy |
169,648
+142,209
| +518% | +$675K | ﹤0.01% | 8612 |
|
|
2021
Q3 | $133K | Sell |
27,439
-16
| -0.1% | -$88 | ﹤0.01% | 12519 |
|
|
2021
Q2 | $187K | Buy |
+27,455
| New | +$222K | ﹤0.01% | 12239 |
|
|
2021
Q1 | – | Sell |
-48,540
| Closed | -$350K | – | 13885 |
|
|
2020
Q4 | $303K | Buy |
+48,540
| New | +$286K | ﹤0.01% | 9063 |
|
|
2020
Q3 | – | Sell |
-35,672
| Closed | -$177K | – | 10953 |
|
|
2020
Q2 | $186K | Buy |
35,672
+6,882
| +24% | +$30.6K | ﹤0.01% | 8584 |
|
|
2020
Q1 | $91K | Sell |
28,790
-54,984
| -66% | -$203K | ﹤0.01% | 8691 |
|
|
2019
Q4 | $338K | Buy |
83,774
+560
| +0.7% | +$1.94K | ﹤0.01% | 7412 |
|
|
2019
Q3 | $360K | Sell |
83,214
-31,036
| -27% | -$124K | ﹤0.01% | 7290 |
|
|
2019
Q2 | $456K | Buy |
114,250
+7,639
| +7% | +$36.3K | ﹤0.01% | 6968 |
|
|
2019
Q1 | $572K | Sell |
106,611
-5,652
| -5% | -$36.5K | ﹤0.01% | 6575 |
|
|
2018
Q4 | $576K | Buy |
112,263
+59,171
| +111% | +$449K | ﹤0.01% | 6192 |
|
|
2018
Q3 | $515K | Sell |
53,092
-226,971
| -81% | -$2.29M | ﹤0.01% | 6642 |
|
|
2018
Q2 | $2.86M | Buy |
280,063
+129,212
| +86% | +$1.46M | ﹤0.01% | 3557 |
|
|
2018
Q1 | $1.96M | Buy |
150,851
+118,679
| +369% | +$1.77M | ﹤0.01% | 3767 |
|
|
2017
Q4 | $576K | Sell |
32,172
-61,505
| -66% | -$1.28M | ﹤0.01% | 5431 |
|
|
2017
Q3 | $2.35M | Buy |
93,677
+38,716
| +70% | +$901K | ﹤0.01% | 3222 |
|
|
2017
Q2 | $1.32M | Sell |
54,961
-50,889
| -48% | -$1.12M | ﹤0.01% | 3702 |
|
|
2017
Q1 | $2.04M | Buy |
105,850
+94,610
| +842% | +$1.49M | ﹤0.01% | 3054 |
|
|
2016
Q4 | $173K | Buy |
+11,240
| New | +$146K | ﹤0.01% | 6406 |
|
|
2015
Q3 | – | Sell |
-3,319
| Closed | -$86K | – | 9328 |
|
|
2015
Q2 | $86K | Buy |
+3,319
| New | +$94.2K | ﹤0.01% | 7238 |
|
Citadel Advisors's PRTK Position: Q1 2023 in Review
Citadel Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 203,159 shares — an estimated $401K sold.
Citadel Advisors first reported a position in PRTK in Q2 2015 and held it in 24 quarters. The position peaked at $2.86M in Q2 2018. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.
- Citadel Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 203,159 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $401K.
- Citadel Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's Paratek Pharmaceuticals, Inc. position peaked at $2.86M in Q2 2018.
- 63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.